Ignite Creation Date:
2024-05-06 @ 7:04 PM
Last Modification Date:
2024-10-26 @ 3:00 PM
Study NCT ID:
NCT05886049
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2023-06-01
Brief Title:
Testing the Addition of an Anti-cancer Drug SNDX-5613 to the Standard Chemotherapy Treatment Daunorubicin and Cytarabine for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLLKMT2A Gene
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Organization Data
Organization:
National Cancer Institute NCI
Class:
NIH
Study ID:
NCI-2023-04141
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Cancer Institute NCI
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None